WO2011156617A3 - Anticorps anti-egfr - Google Patents

Anticorps anti-egfr Download PDF

Info

Publication number
WO2011156617A3
WO2011156617A3 PCT/US2011/039821 US2011039821W WO2011156617A3 WO 2011156617 A3 WO2011156617 A3 WO 2011156617A3 US 2011039821 W US2011039821 W US 2011039821W WO 2011156617 A3 WO2011156617 A3 WO 2011156617A3
Authority
WO
WIPO (PCT)
Prior art keywords
egfr
egfr antibodies
antibodies
activation
egfrviii
Prior art date
Application number
PCT/US2011/039821
Other languages
English (en)
Other versions
WO2011156617A2 (fr
Inventor
Fang Wang
Sylvie Vincent
William M. Winston, Jr.
Steve Botega
Donna Mcintosh
Ting Chen
Steven Tyler
Jeno Gyuris
Original Assignee
Aveo Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals, Inc. filed Critical Aveo Pharmaceuticals, Inc.
Publication of WO2011156617A2 publication Critical patent/WO2011156617A2/fr
Publication of WO2011156617A3 publication Critical patent/WO2011156617A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps monoclonaux qui se lient à un membre associé au récepteur du facteur de croissance épidermique EGFRL858R/T790M et inhibent son activation. Lesdits anticorps peuvent être utilisés pour traiter maladies et troubles prolifératifs cellulaires, notamment certaines formes de cancer, associés à une activation de l'amplification d'EGFRL858R/T790M, d'EGFRvIII ou d'EGFR de type sauvage.
PCT/US2011/039821 2010-06-09 2011-06-09 Anticorps anti-egfr WO2011156617A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35311810P 2010-06-09 2010-06-09
US61/353,118 2010-06-09

Publications (2)

Publication Number Publication Date
WO2011156617A2 WO2011156617A2 (fr) 2011-12-15
WO2011156617A3 true WO2011156617A3 (fr) 2012-03-01

Family

ID=44588165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/039821 WO2011156617A2 (fr) 2010-06-09 2011-06-09 Anticorps anti-egfr

Country Status (1)

Country Link
WO (1) WO2011156617A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6441792B2 (ja) 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
TWI641619B (zh) * 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2879712B1 (fr) 2012-07-31 2018-04-25 Crown Bioscience, Inc. (Taicang) Marqueurs histologiques pour l'identification de patients atteints d'un carcinome du poumon non à petites cellules pour le traitement par un médicament anti-egfr
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
ES2855075T3 (es) * 2014-10-17 2021-09-23 Novartis Ag Combinación de ceritinib con un inhibidor de EGFR
CN106124775B (zh) * 2016-06-30 2018-10-30 广州瑞博奥生物科技有限公司 小鼠抗体亚型快速分型试剂盒及其制备方法
EP3621647A1 (fr) 2017-05-11 2020-03-18 Nantkwest, Inc. Compositions de cellules nk anti-egfr/haute affinité et procédés de traitement du chordome
CN111116754A (zh) * 2018-10-30 2020-05-08 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性tcr及其应用
CN116333119B (zh) * 2021-12-16 2024-02-23 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1612558A1 (fr) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Procédé de dosage du gluten
WO2008091701A2 (fr) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Utilisation d'anticorps anti-egfr dans le traitement de maladie médiée par des mutants de récepteur du facteur de croissance épidermique (egfr)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2082160C (fr) 1991-03-06 2003-05-06 Mary M. Bendig Anticorps monoclonaux humanises et chimeriques
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2507749C (fr) 1991-12-13 2010-08-24 Xoma Corporation Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
KR20090125840A (ko) 2001-06-13 2009-12-07 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간 모노클로날 항체
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2004006955A1 (fr) 2001-07-12 2004-01-22 Jefferson Foote Anticorps super humanises
WO2003012072A2 (fr) 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Anticorps monoclonaux se liant a des elements actives de la famille erbb et leurs procedes d'utilisation
US20050222059A1 (en) 2002-02-25 2005-10-06 Tang Careen K Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer
AU2003239505A1 (en) 2002-05-20 2003-12-12 Amgen Fremont Inc. Treatment of renal carcinoma using antibodies against the egfr
CN104059147A (zh) 2003-06-27 2014-09-24 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1612558A1 (fr) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Procédé de dosage du gluten
WO2008091701A2 (fr) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Utilisation d'anticorps anti-egfr dans le traitement de maladie médiée par des mutants de récepteur du facteur de croissance épidermique (egfr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PEREZ-TORRES MARIANELA ET AL: "Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations", THE JOURNAL OF BIOLOGICAL CHEMISTRY 29 DEC 2006,, vol. 281, no. 52, 29 December 2006 (2006-12-29), pages 40183 - 40192, XP002576289 *

Also Published As

Publication number Publication date
WO2011156617A2 (fr) 2011-12-15

Similar Documents

Publication Publication Date Title
WO2011156617A3 (fr) Anticorps anti-egfr
WO2011136911A3 (fr) Anticorps anti-erbb3
WO2011143318A3 (fr) Anticorps anti-fgfr2
MY192474A (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
WO2013006547A3 (fr) Anticorps dirigés contre le récepteur du facteur de croissance épidermique (egfr) et leurs utilisations
WO2012058592A3 (fr) Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci
WO2015038984A3 (fr) Anticorps anti-récepteur du facteur de croissance épidermique modifiés et procédés pour les utiliser
WO2010002862A3 (fr) Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
PH12014502641B1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
MX2015007751A (es) Anticuerpos anti-gdf15.
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
SG10201808837RA (en) Anti-egfr antibodies and antibody drug conjugates
WO2015069794A3 (fr) Nouveaux anticorps anti-claudine et leurs méthodes d'utilisation
PH12017500864A1 (en) Anti-notch1 antibodies
WO2013119960A3 (fr) Nouveaux modulateurs et procédés d'utilisation
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
NZ604003A (en) Monoclonal antibodies against her2
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
WO2015050959A8 (fr) Anticorps anti-kits et leurs méthodes d'utilisation
WO2012033987A3 (fr) Anticorps anti-récepteur bêta de folate humain et leurs procédés d'utilisation
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2014172653A3 (fr) Anticorps anti-notch1
NZ729725A (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11731582

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11731582

Country of ref document: EP

Kind code of ref document: A2